53 results about "Renal anemia" patented technology

The invention discloses a slow-release microsphere preparation containing a recombined human haemopoietin. The slow-release microsphere preparation is prepared by the S/O/W compound emulsion solvent volatilization method. The preparation method comprises that: firstly, by the freeze-drying method, a micro particle containing the human serum albumin and the recombined human haemopoietin is prepared; secondly, by using a biodegradable high molecular material of lactic acid-glycollic acid block copolymer as a carrier material, the micro particle containing the human serum albumin and the recombined human haemopoietin is encapsulated; and thirdly, the lactic acid-glycollic acid block copolymer slow-release microsphere preparation containing the recombined human haemopoietin is prepared. The microsphere of the invention has the advantages of smooth surface, uniform appearance, regular size and no adhesion, the average particle size is between 70 and 105mu m; moreover, the microsphere is high in drug-carrying quantity and encapsulating rate, and the in vitro slow release period is more than 30 days. The obtained slow-release microsphere preparation is good in biocompatibility and can be used for non-intravenous drug administration such as hypodermic drug administration and intramuscular drug administration, and when used as a drug preparation for treating renal anemia, the slow-release microsphere preparation can improve the hematocrit of a patient.

The invention discloses new application of sodium ferrous chlorophyll to the promotion of erythropoiesis, and belongs to the field of medicines. Sodium ferrous chlorophyll has the effect of erythropoietin, and can be prepared into medicaments for treating anemia such as 'anemia of chronic disease' or 'renal anemia' which are caused by hyposecretion in erythropoietin.

The present invention relates to a preventive or therapeutic agent for pathological conditions caused by reduced production of erythropoietin, or for anemia, or for chronic anemia, renal anemia, aplastic anemia, or pure red cell aplasia, the agent comprising, as an active ingredient, a cyclic amine compound represented by the following formula (1):

wherein,

• • R¹, R² and R³ each independently represent a hydrogen atom, a halogen atom, or hydroxy, alkyl, halogen-substituted alkyl, alkoxy, alkylthio, carboxyl, alkoxycarbonyl or alkanoyl group;
  • W¹ and W² each independently represent N or CH;
  • X represents O, NR⁴, CONR⁴ or NR⁴CO;
  • R⁴ each represents a hydrogen atom, or an alkyl, alkenyl, alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aralkyl, or substituted or unsubstituted heteroaralkyl group; and l, m and n each represents a number of 0 or 1, or a salt thereof or a solvate thereof.

This invention concerns adamantanamines (e.g. memantine, amantadine, and rimantadine) and neramexane salts of thiomolybdic and thiotungstic acids, including their preparation and pharmaceutical compositions, as dual acting drugs. These salts are used to treat or potentially arrest the neurodegenerative pathophysiology, clinical signs and symptoms of dementia of the Alzheimer's type, Parkinson's, Huntington's, AIDS-related dementia and Schizophrenia and its cognitive deficits. Additional uses of these derivatives include antiviral activity. The novel compositions of the present invention appear particularly useful in enhancing the therapeutic benefits of copper-sequestering tetrathiomolybdates in treating elevated copper-induced toxicities in neurologically presenting Wilson's disease, and in treating diseases of the inflammatory etiology and abnormal copper biochemistry, such as tumor angiogenesis, liver cirrhosis, hepatitis, pulmonary fibrosis and other fibrotic diseases, cardiovascular disease, cerebral ischemia, renal anemia, rheumatoid arthritis, diabetes, obesity, gastrointestinal disorders, and eye diseases such as glaucoma, proliferative diabetic retinopathy, and age related macular degeneration. These compounds have excellent stability and aqueous solubility for good oral bioavailability.

The invention discloses a recombinant human erythropoietin-CTP fusion protein production process. The process is characterized in that a microcarrier suspension perfusion culture technology or a serum-free suspension fed-batch culture technology is adopted as a recombinant engineering cell line culture manner. The invention also discloses a recombinant human erythropoietin-CTP fusion protein purifying process. Through optimization, a simple process flow is obtained, such that high-purity and high-activity recombinant human erythropoietin-CTP fusion protein is obtained. The invention also relates to the ticokinetics study of the recombinant human erythropoietin-CTP fusion protein in monkey bodies, and the application of the recombinant human erythropoietin-CTP fusion protein in treating rat renal anemia.

The invention provides application of Shenkang injection in preparation of a medicament for treating chronic renal failure complication or complication caused by peritoneal dialysis or blood dialysis. The Shenkang injection can be administrated in an intravenous infusion mode, or mixed with conventional dialysate and administrated or prepared into Chinese medicinal dialysate for dialytic administration. Animal experiments prove that the Shenkang injection can reduce the blood pressure, raises the N0 level, reduces the endothelin (ET) level, treats pulmonary edema, reduces the pulmonary coefficient and the pulmonary water content, improves renal anemia and treats peritoneal inflammation. The Shenkang injection has the advantages that the dialysis frequency is reduced, the occurrence of dialysis complication is reduced, the peritoneum is well protected, the dialysis effect is improved, the medical cost is reduced, further failure of the kidney is well delayed, the kidney is protetcted and the quality of life of a patient is improved.

The invention relates to a composition for preventing and/or treating a chronic kidney disease. The composition for preventing and/or treating the chronic kidney disease is prepared from the followingcomponents in parts by weight: icariin, rheum emodin, ferulic acid and ligustrazine, wherein the ratio of the icariin to the rheum emodin to the ferulic acid to the ligustrazine is 1.3 to 1.2 to 1.3to 1. An experiment result shows that the composition interferes with signaling pathway activation of a fibrosis promoting central event TGF-beta/Smad/EZH2 by restraining Smad3 phosphorylation and EZH2 activity, and renal interstitial fibrosis is resisted. By protecting renal innate cells, a hypoxia-inducible factor HIF-2alpha is stabilized, synthesis of endogenous EPO is increased, an iron metabolism disorder caused by high expression of Hepcidin-25 is antagonized, renal anemia is improved, and a renal failure is delayed. The invention further relates to application of the composition to preparation of drugs for preventing and/or treating the chronic kidney disease. The composition for preventing and/or treating the chronic kidney disease has the advantages that a preparation method is simple and convenient, the components work collaboratively, the therapeutic effect is good, and good application prospects are achieved.

A therapeutic and/or prophylactic agent for renal anemia comprising ALAs and an erythropoietin production promoter comprising ALAs.

The invention discloses a preparation method and medical application of benzisothiazole and benzothiophene, and telates to the field of pharmaceutical chemistry. According to the invention, benzisothiazole and benzothiophene are the first type of HIF-2 agonists; compared with a compound M1001 found by the applicant in the earlier stage, the invention has better HIF-2 agonist activity, and has remarkable enhancement activity on expression of mRNA and protein of EPO, VGEF, Glut1, NDRG1 and the like at the downstream of HIF-2, so that the invention can be used for preparing drugs for treating and/or preventing chronic kidney diseases/chronic renal anemia, dyslipidemia and high cholesterol caused by abnormal expression of HIF-2; and the method has a good industrialization prospect.

The invention relates to an application of anhydroicaritin in preparation of medicine for treating anaemia, which belongs to the medicine field. The application of anhydroicaritin in preparation of medicine for treating anaemia solves the technical disadvantages of poor treatment effect of the current medicines and high price of the medicines. The invention also provides a medicine for treating anaemia by taking anhydroicaritin as active component. The pharmacological experiment displays that the anhydroicaritin has active treatment effect for aplastic anemia, anemia of inflammation, hemolytic anaemia, renal anemia or its combination. The anhydroicaritin for treating anaemia has the advantages of clear effect mechanism, clear composition, definite therapeutic effect and wide medical science application prospect.

This invention relates to a solution preparation of recombinant human erythropoietin. The preparation is prepared from recombinant human erythropoietin, recombinant human serum albumin, sodium citrate, and sodium chloride buffer. It can be used for treating renal anemia, preoperative surgical red blood cell mobilization, and anemia due to chemotherapy of tumor.

The invention provides a method for building a mouse renal anemia animal model. The method comprises the following steps: 1) preparing a 0.4 mg/mL aristolochic acid solution from aristolochic acid with PBS (Phosphate Buffer Saline); 2) injecting the aristolochic acid solution into the enterocoelia of a mouse for 6 weeks, 3 mg/kg once every 3 days, and detecting anemia, renal function index, renalpathology and capability of secretion of hemopoietin; 3) stopping administration for 6 weeks, and observing the previous indexes again. The mouse renal anemia animal model built by the method is stable and has high modeling rate, and the problem that renal anemia has a higher incidence rate among chronic kidney diseases but a mature renal anemia animal model is lacked at present is solved.

The invention relates to ethanol extracting solution of desmodium renifolium and an application thereof and belongs to the field of medicines. The ethanol extracting solution has the beneficial effects that the desmodium renifolium as a Dai medicine has an effect of preventing and treating chronic renal failure, and the mechanism is associated with improvement of renal anemia of a rat with chronicrenal failure and reduction of renal injury and renal interstitial fibrosis degree. The invention provides an application direction of the desmodium renifolium, the ethanol extracting solution and water extracting solution thereof in preventing and treating the chronic renal failure, provides a preparation method of desmodium renifolium tablets and provides pharmacodynamic basis for further research and development of the desmodium renifolium tablets.

The invention provides an application of myricetin in preparing a preparation for inhibiting hepcidin expression. Specifically, myricetin can be used for preparing a food supplement or a medicament for preventing and treating anemia of chronic inflammation (ACI), iron-refractory iron deficiency anemia (IRIDA) or renal anemia. The invention has the beneficial effects that the application of myricetin in preparing the preparation for inhibiting hepcidin expression provided by the invention provides a theoretical basis for myricetin to alleviate hepcidin increasing disease and especially provides a foundation for research and development of medicaments for anemia of chronic inflammation and iron-deficiency anemia.

The invention discloses a use of a hypoxia-inducible factor prolyl hydroxylase activity inhibitor in the preparation of a drug for preventing and treating acute kidney injury. The HIF prolyl hydroxylase activity inhibitor is Roxadustat (FG-4592). The HIF prolyl hydroxylase activity inhibitor is an HIF family selective inhibitor, and can alleviate pathological damages of cisplatin-induced acute kidney injury to kidneys and improve the functions of the kidneys. The FG-4592 can reduce apoptosis of renal tubular cells and renal tubular functions, improve the pathological injury and renal functionsof the kidneys and protect the structures and the functions of the kidneys in the acute kidney injury by activating HIF1alpha, promoting the expression of EPO and HO-1, inhibit apoptosis and down-regulate the release of inflammatory factors. The FG-4592 is currently in a Phase III clinical research stage in the field of prevention and treatment of chronic renal anemia, and it is found that the FG-4592 is highly possible to provide the effective clinical drug for preventing and treating the AKI.

There is provided an agent for preventing or treating renal anemia, which contains arginine as an active ingredient. This agent for preventing or treating renal anemia can be easily administered and the administration can be controlled at home to obtain excellent effect in preventing or treating renal anemia.

The present invention relates to the use of ligustrazine nitrone derivatives and pharmaceutical composition thereof for the treatment and prevention of diseases of diabetic complications, which include renal anemia. The ligustrazine nitrone derivatives have the structure of the general formula (I).

Experimental results indicated that the ligustrazine nitrone derivatives can significantly increase the levels of serum iron and erythropoietin in STZ induced SD rats and spontaneously hypertensive rats, and can be used for treating and preventing renal anemia caused by decrease in renal EPO production and/or concomitant iron deficiency. Therefore, the ligustrazine nitrone derivatives can be made into various dosage forms with a drug carrier. The derivatives can be prepared into various dose forms together with drug carriers.

The invention discloses a crystal form of roxadustat, a preparation method of the crystal form, a pharmaceutical composition of roxadustat and an application of the crystal form in preparation of pharmaceutical preparations for treating diseases such as chronic renal anemia. The crystal form provided by the invention has good stability and druggability, and the preparation process is stable and simple to operate. The structure of roxadustat is shown in the specification;.